



TECH CENTER 1600/2900

FEB 06 2002

RECEIVED

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

20488/12-US

SERIAL NO.

10/014,291

APPLICANT(S): von Hoersten, et al.

FILING DATE:

10/26/2001

ART UNIT:

Not yet assigned

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB CLAS S	FIL. DATE IF APPR
/	AA	2,961,377	11-22-1960	Shapiro et al.	167	65	
/	AB	3,960,949	6-1-1976	Ahrens et al.	260	564 B	
/	AC	5,433,955	7-18-1995	Bredehorst et al.	424	94.3	
OC	AD	5,614,379	3-25-1997	MacKellar	435	68.1	
/	AE	5,624,894	4-29-1997	Bodor	514	2	
/	AF	4,935,493	6-19-1990	Bachovchin et al.	530	331	
/	AG	5,512,549	4-30-1996	Chen et al.	514	12	
/	AH	6,006,753	12-28-1999	Efendic	128	898	8/21/97

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
/	BA	WO 00/53171	9-14-00	PCT	A61K	31/155	Y
/	BB	DT 25 42598 A1	4-22-76	Germany	C07C	129/16	N
OC	BC	FR 2696740	4-15-94	France	C07D	207/40 4	N
/	BD	FR 2085665	3-3-71	France	A61K	27/00	N
/	BE	WO 97/40832	11-6-97	PCT	A61K	31/425	Anstract only
/	BF	WO 95/15309	6-8-95	PCT	C07D	207/16	Y



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

20488/12-US

SERIAL NO.

10/014,291

APPLICANT(S): von Hoersten, et al.

FILING DATE:

10/26/2001

ART UNIT:

Not yet assigned

RECEIVED
FEB 06 2002
TECH CENTER 1600/2900

	BG	JP 4334357	11-20-92	JAPAN	C07C	233/57	Abstract only
	BH	WO 93/08259	4-29-93	PCT	C12N		Y
OC	BI	WO 95/11689	5-4-95	PCT	A61K	37/00	Y
	BJ	WO 97/45117	12-4-97	PCT	A61K	31/435	Y
	BK	DE 196 16 486 A1	10-30-97	GERMANY	A61K	39/395	N
	BL	WO 95/29691	11-09-95	PCT	A61K	38/00	Y
	BM	WO 98/22494	5-28-98	PCT	C07K	005/00	Y
	BN	WO00/01849	01-13-2000	PCT	A61K	31/155	Y

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	CA	Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, "Sulphonylureas and metformin: efficacy and inadequacy". 3:33-51 (1990).
	CB	Mercla Index, 11 th Edition, Page 934 , 1979 oc
	CC	Martindale The Extra Pharmacopeia, 30 th Edition, Pharmaceutical Press, 1993, Page 1619
OC	CD	CHEMICAL ABSTRACTS, vol. 115. No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"
	CE	CHEMICAL ABSTRACTS, vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides"
	CF	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21. Juni 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)
	CG	ARAI ET AL: "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain" CHEMICAL AND PHARMACEUTICAL BULLETIN., Bd. 41, Nr. 9, 1993



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY DOCKET NO.

20488/12-US

SERIAL NO.

10/014,291

APPLICANT(S): von Hoersten, et al.

FILING DATE:

10/26/2001

ART UNIT:

Not yet assigned

RECEIVED
 FEB 06 2002
 TECH CENTER 1600/2900

	CH	J. Lin et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, Vol. 95, November 1998, pages 14020-14024.
	CI	KOROM, S., et al "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients", Transplantation Vol. 63, 1495 – 1500 No. 10 (1997)
	CJ	TANKA, S., et al., "Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV". Int. J. Immunopharmacol", Vol 19, No. 1 Pages 15-24, 1997
	CK	MENTLEIN, R., et al., "Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV". Regul. Pept. 49, 133 -144(1993)
	CL	WETZL, W., et al., "Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes". Neuropeptides, 31, 41- 45 (1997)
OC	CM	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in Xenopus Laevis oocytes". J. Physiol. 504, 169-174 (1997)
	CN	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Association with Other Laboratory Parameters". Clin Chem Lab Med 2001, February; 39 (2) :155-9, 1 page.
	CO	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". Histochem J, 1985, July; 17 (7) :737-71, 1 page.
	CP	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". Acta Histochem 1993, December, 1995 (2) :185-92, 1 page.
	CQ	HEYMANN, E.; et al.; "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." Klin Wochenschr, 1984, January, 2;62 (1) :2-10, 1 page.
	CR	MAGYAR, C.E.; et al.; "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." Am J Physiol Renal Physiol, 2000, August; 279 (2) :F358-69, 1 page.
OC	CS	PAPIES, B.; et al.; "Isoenzyme (Lactate "Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." Cor Vasa, 1991; 33 (3) :218-26, 1 page.



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO.	SERIAL NO.
	20488/12-US	10/014,291
	APPLICANT(S): von Hoersten, et al.	
	FILING DATE:	ART UNIT:
	10/26/2001	Not yet assigned

/	CT	QURESHI. N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". Regul Pept, 1998, September 25; 75-76:215-20, 1 page.
OC	CU	Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pages 728-729.
/	CV	The Merck Index, 9 th Edition, 1976, page 773.
/	CW	C.J. Bailey et al., <u>New Antidiabetic Drugs</u> , Smith-Gordon Nishimura, 1990, page 36.
/		
/		
Examiner: <i>Chung</i>		Date: <i>06/06/02</i>




RECEIVED

OCT 21 2002 Page 5 of 7

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 20488/12		SERIAL NO. 10/014,291	
				APPLICANT(S): Von Horsten et al.			
				FILING DATE: October 26, 2001		ART UNIT: 1614 / 1646	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
	AA	3,174,901	3/23/65	Sterne	167	65	
	AB	3,879,541	4/22/75	Kabbe et al.	424	326	
	AC	4,028,402	6/7/77	Fischer et al.	260	501.14	
OC	AD	4,935,493	6/19/90	Bachovchin et al	530	331	
	AE	5,462,928	10/31/95	Bachovchin et al.	514	19	
	AF	5,512,549	4/30/96	Chen et al.	514	12	
	AG	5,543,396	8/6/96	Powers et al.	514	19	
	AH	5,939,560	8/17/99	Jenkins et al.	548	535	
	AI	6,006,753	12/28/99	Efendic	128	898	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
	BA	WO 01/62266 A2	08/30/01	PCT	A61K	38/00	Y
	BB	WO 00/01849	01/13/00	PCT	C12Q	1/68	Y
	BC	EP 0 995 440 A1	4/26/00	EPO	A61K	31/425	N
OC	BD	WO 91/11457	08/8/91	PCT	C07K	7/34	Y
	BE	WO 91/16339	10/31/91	PCT	C07K	5/10	Y
	BF	WO 98/19998	5/14/98	PCT	C07D	207/00	Y
	BG	WO 91/17767	11/28/91	PCT	A61K	37/54	Y
	BH	JP 04-288098	10/13/92	JP	A61K	37/64	(Abstract Only)
	BI	* WO 99/46272 A	09/16/99	PCT	C07F	9/572	Y
	BJ	* DE 299 09 210 U	09/09/99	GERMANY	A61K	31/425	N
Examiner: <i>[Signature]</i>				Date: 06/06/03			



RECEIVED

Page 6 of 7

OCT 21 2002

TECH CENTER 1600/2900

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20488/12	SERIAL NO. 10/014,291
	APPLICANT(S): Von Horsten et al.	
	FILING DATE: October 26, 2001	ART UNIT: 1614 /646


OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	CA	The Merck Index, 12 th Edition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, Page 1014.
	CB	Martindale The Extra Pharmacopoeia, 30 th Edition, London Pharmaceutical Press, 1993, Page 36.
	CC	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Association with Other Laboratory Parameters". <u>Clin Chem Lab Med</u> 2001, February; 39 (2) :155-9, 1 page.
	CD	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". <u>Histochem J</u> , 1985, July; 17 (7) :737-71, 1 page.
	CE	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". <u>Acta Histochem</u> 1993, December, 95 (2) :185-92, 1 page.
	CF	HEYMANN, E.; et al.; "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." <u>Klin Wochenschr</u> , 1984, January, 2;62 (1) :2-10, 1 page.
	CG	MAGYAR, C.E.; et al.; "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." <u>Am J Physiol Renal Physiol</u> , 2000, August; 279 (2) :F358-69, 1 page.
OC	CH	PAPIES, B.; et al.; "Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." <u>Cor Vasa</u> , 1991; 33 (3) :218-26, 1 page.
	CI	QURESHI, N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". <u>Regul Pept</u> , 1998, September 25; 75-76:215-20, 1 page.
	CJ	Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pages 728-729.
	CK	The Merck Index, An Encyclopedia of Chemicals and Drugs, 9 th Edition, Merck & Co., Inc., 1976, page 773
	CL	C.B. Welch, <u>Medical Management of Non-Insulin-Dependent (Type II) Diabetes</u> , 3 rd edition, American Diabetes Association, "Diagnosis and Classification" p. 3, 1994, Pharmacologic Intervention (2 pages).
	CM	Mannucci et al., <u>Diabetes Care</u> , "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.
	CN	Stryer, <u>Biochemistry</u> 3 rd Ed., "Protein Conformation, Dynamics, and Function", 1988, p 191-193.
	CO	Pauly et al., <u>Regulatory Peptides</u> , "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides", July 15, 1996, 64(1-3): 148 plus cover.
	CP	Gutniak et al., <u>New England Journal of Medicine</u> , "Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus", 1992, 326: 1316-1322.
	CQ	H.A. Smith et al., <u>Veterinary Pathology</u> (fourth edition), "Diseases and Disorders of Metabolism: Deficiency Diseases", 1972, p 1018-1020.
	CR	G.G. Duncan, <u>Diseases of Metabolism (Asian edition)</u> , "Diabetes Mellitus", 1966, p 951-957.

Examiner:

Date:

06/06/03



FORM PTO-1449 PATENT INFORMATION DISCLOSURE STATEMENT	ATTY DOCKET NO. 20488/12	SERIAL NO. 10/014,291
	APPLICANT(S): Von Horsten et al.	
	FILING DATE: October 26, 2001	ART UNIT: 1614 1646

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CS	T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by DP IV", Endocrinology, Vol. 136(8), 1995, p 3585-3596.
CT	C.F. Deacon et al., <u>Diabetes</u> , "Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects", September 1995, 44: 1126-1131.
CU	<u>Vidal</u> , 1993, 69 th Edition, p. 612-613.
CV	<u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , Ninth Edition, 1996, p. 1510.
CW	Nathan et al., <u>Diabetes Care</u> , "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", February 1992, 15(2): 270-275.
CX	<u>Pschyrembel</u> , Kininisches Wörterbuch 257, Auflage, 1994, 9 pages.
CY	Frohman et al., <u>Journal of Clin. Invest.</u> , "Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH ₂ Terminus", Volume 78, October 1986, p 906-913
CZ	Snow et al., <u>Advances In Medicinal Chemistry</u> , "Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents", Vol. 3, 1995, p 149-177.
CAA	Ashworth et al., <u>BIOORG. MED. CHEM. LETT.</u> , "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", 1996, 6(10): 1163-1166.
CAB	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "Dipeptidyl peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn ²⁺ in Vitro", 1990, 75(1): 35-44.
CAC	Lee, H.S. et al., "Cathepsin B Inhibitory Peptides Derived from β -Casein," Peptides 21 (2000) 807-809.
CAD	Edwards, J.V. et al., <u>J. Peptide Res.</u> , "Synthesis and Activity of NH ₂ - and COOH-Terminal Elastase Recognition Sequences on Cotton," 1999, 54: 536-543.
CAE	* Wettstein, J.G. et al. <u>Pharmacology & Therapeutics</u> , "Central Nervous System Pharmacology of Neuropeptide Y.", 1995, 65(3): 397-414.
CAF	* Badia-Elder N.E. et al., <u>Alcoholism Clinical and Experimental Research</u> , "Effects of Neuropeptide Y (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (HAD1/LAD1) Rats.", 2000, 24(5): 82A.
CAG	* Munglani R. et al., <u>Drugs, Adis International Ltd, At</u> , "The Therapeutic Potential of Neuropeptide Y Analgesic, Anxiolytic and Antihypertensive", 1996 52(3): 371-389.

Examiner:

Date: